Argenica\u5728\u4e0a\u4e2a\u6708\u4e0b\u65ec\u4e0e\u73c0\u65af\u7684\u4e34\u5e8a\u7814\u7a76\u673a\u6784\u7ebf\u6027\u4e34\u5e8a\u7814\u7a76\u8fdb\u884c\u4e86\u5408\u4f5c\u3002<\/a><\/p>\nLinear\u6709\u4e00\u4e2a\u4e13\u95e8\u5efa\u9020\u7684\u8bbe\u65bd\uff0c\u5728\u5c3c\u5fb7\u5170\u7684QEII\u533b\u7597\u4e2d\u5fc3\u8fd0\u4f5c\uff0c\u5e76\u6709\u4e00\u4e2a\u7ea629,000\u540d\u5065\u5eb7\u5fd7\u613f\u8005\u7684\u6570\u636e\u5e93\uff0c\u5c06\u7528\u4f5c\u8bd5\u9a8c\u7684\u62db\u52df\u5e93\u3002<\/p>\n
Argenica\u5df2\u8058\u8bf7Linear\u516c\u53f8\u627f\u62c5\u8bd5\u9a8c\u7684\u521d\u6b65\u5de5\u4f5c\uff0c\u5305\u62ec\u719f\u6089\u65b9\u6848\u3001\u5efa\u7acb\u4e34\u5e8a\u573a\u6240\u7ba1\u7406\u3001\u51c6\u5907\u4f26\u7406\u63d0\u4ea4\u3001\u9884\u8ba2\u8bd5\u9a8c\u671f\u95f4\u7684\u4e34\u5e8a\u5e8a\u4f4d\u4ee5\u53ca\u5efa\u7acb\u4e34\u5e8a\u7814\u7a76\u76d1\u6d4b\u3002<\/p>\n
\u7b2c\u4e00\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c<\/h2>\n
\u8be5\u8bd5\u9a8c\u5c06\u5305\u62ec\u56db\u4e2a\u961f\u5217\uff0c\u6bcf\u4e2a\u961f\u5217\u5305\u62ec8\u540d\u5065\u5eb7\u7684\u4eba\u3002<\/p>\n
\u6bcf\u4e2a\u961f\u5217\u5c06\u63a5\u53d7\u4e0d\u540c\u5242\u91cf\u7684ARG-007\u3002\u5728\u6bcf\u4e2a\u961f\u5217\u4e2d\uff0c6\u540d\u53d7\u8bd5\u8005\u5c06\u63a5\u53d7\u6307\u5b9a\u5242\u91cf\u7684ARG-007\uff0c\u800c2\u540d\u53d7\u8bd5\u8005\u5c06\u63a5\u53d7\u5b89\u6170\u5242\u3002<\/p>\n
Argenica\u9884\u8ba1\uff0c1\u671f\u4e34\u5e8a\u8bd5\u9a8c\u5c06\u9700\u89816\u4e2a\u6708\u7684\u65f6\u95f4\u5b8c\u6210\uff0c\u5e76\u5728\u5065\u5eb7\u4eba\u7c7b\u60a3\u8005\u4e2d\u4f7f\u7528ARG-007\u65f6\u63d0\u4f9b\u6709\u5173\u5176\u5b89\u5168\u6027\u3001\u8010\u53d7\u6027\u548c\u836f\u4ee3\u52a8\u529b\u5b66\u7684\u6570\u636e\u3002<\/p>\n
\u8be5\u8bd5\u9a8c\u8fd8\u5c06\u8bc4\u4f30\u7ed9\u836f\u5242\u91cf\u7684\u5b89\u5168\u6027\uff0c\u5e76\u76d1\u6d4b\u4efb\u4f55\u4e0d\u826f\u53cd\u5e94\u548c\u4e00\u822c\u8010\u53d7\u6027\u3002<\/p>\n
\u8fdb\u51652\u671f\u4e34\u5e8a\u7814\u7a76<\/h2>\n
\u6765\u81ea1\u671f\u4eba\u4f53\u7814\u7a76\u7684\u6570\u636e\u5c06\u652f\u63012\u671f\u8bd5\u9a8c\u7684\u8def\u7ebf\u56fe\uff0c\u5176\u4e2dARG-007\u5c06\u7528\u4e8e\u4e2d\u98ce\u60a3\u8005\u3002<\/p>\n
ARG-007\u7684\u6700\u7ec8\u76ee\u6807\u662f\u7acb\u5373\u7ed9\u836f\uff0c\u4ee5\u51cf\u5c11\u534a\u6697\u5e26\u7ec6\u80de\u7684\u6b7b\u4ea1\u3002<\/p>\n
\u8fd9\u5c06\u6539\u5584\u75c5\u4eba\u7684\u9884\u540e\u5e76\u51cf\u5c11\u6062\u590d\u65f6\u95f4\u3002<\/p>\n
Argenica\u6307\u51fa\uff0c1\u671f\u4e34\u5e8a\u6570\u636e\u4e5f\u53ef\u80fd\u7528\u4e8e\u52a0\u901fARG-007\u6cbb\u7597\u5176\u4ed6\u7c7b\u578b\u8111\u635f\u4f24\u7684\u4e34\u5e8a\u5f00\u53d1\uff0c\u5305\u62ec\u56f4\u4ea7\u671f\u7f3a\u6c27\u7f3a\u8840\u6027\u8111\u75c5\u3001\u521b\u4f24\u6027\u8111\u635f\u4f24\u548c\u8111\u9707\u8361\uff0c\u4ee5\u53ca\u624b\u672f\u8bf1\u53d1\u7684\u4e2d\u98ce\u3002<\/p>\n
Argenica\u7684\u613f\u666f<\/h2>\n
\u6839\u636eArgenica\u7684\u8bf4\u6cd5\uff0c\u76ee\u524d\u4e2d\u98ce\u60a3\u8005\u7684\u62a4\u7406\u6807\u51c6\u662f\u9488\u5bf9\u4e2d\u98ce\u7684\u6cbb\u7597\u548c\u8bca\u65ad\uff0c\u800c\u4e0d\u662f\u5bf9\u8111\u7ec6\u80de\u7684\u4fdd\u62a4\u3002<\/p>\n
\u636e\u4f30\u8ba1\uff0c\u9002\u5f53\u7684\u4e2d\u98ce\u6cbb\u7597\u6bcf\u5ef6\u8fdf\u4e00\u4e2a\u5c0f\u65f6\uff0c\u5927\u8111\u5c31\u4f1a\u8870\u80013.6\u5e74\uff0c\u8fd9\u610f\u5473\u7740\u53ca\u65f6\u8bca\u65ad\u548c\u6cbb\u7597\u5bf9\u75c5\u4eba\u7684\u9884\u540e\u81f3\u5173\u91cd\u8981\u3002<\/p>\n
\u5206\u6790\u4eba\u58eb\u9884\u6d4b\uff0c\u52302030\u5e74\uff0c\u5168\u7403\u4e2d\u98ce\u6cbb\u7597\u8d39\u7528\u5c06\u8fbe\u52301830\u4ebf\u6fb3\u5143\u3002<\/p>\n
ARG-007\u662f\u4e00\u79cd\u5bcc\u542b\u7cbe\u6c28\u9178\u7684\u9633\u79bb\u5b50\u591a\u80bd\uff0c\u88ab\u8bbe\u8ba1\u7528\u6765\u4fdd\u62a4\u5927\u8111\u7ec4\u7ec7\u5728\u4e2d\u98ce\u671f\u95f4\u514d\u53d7\u635f\u4f24\uff0c\u5e76\u589e\u52a0\u4e2d\u98ce\u540e\u6062\u590d\u7684\u673a\u4f1a\u3002<\/p>\n
Argenica\u7684\u613f\u666f\u662f\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u6cbb\u7597\u836f\u7269\uff0c\u5982ARG-007\uff0c\u53ef\u4ee5\u5e2e\u52a9\u4e2d\u98ce\u60a3\u8005\u5728\u5c3d\u53ef\u80fd\u65e9\u7684\u9636\u6bb5\u6700\u5c0f\u5316\u4f24\u5bb3\u548c\u6539\u5584\u7ed3\u679c\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"
\u7ecf\u8fc7\u5e7f\u6cdb\u7684\u7814\u7a76\u548c\u4e34\u5e8a\u524d\u7814\u7a76\uff0cArgenica Therapeutics (ASX: AGN)\u6b63\u51c6\u5907\u4e8e\u660e\u5e74\u7b2c\u4e00\u5b63\u5ea6\u5f00\u59cb\u5176\u5352\u4e2d\u6cbb\u7597\u836f\u7269ARG-007\u76841\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002 \u8be5\u516c\u53f8\u516c\u5e03\u4e86\u5f00\u59cb\u8bd5\u9a8c\u7684\u8def\u7ebf\u56fe\uff0c\u52a8\u7269\u4f53\u5185\u7684\u6700\u7ec8\u836f\u4ee3\u52a8\u529b\u5b66\u548c\u5b89\u5168\u6bd2\u7406\u5b66\u7814\u7a76\u9884\u8ba1\u5c06\u5728\u4eca\u5e74\u665a\u4e9b\u65f6\u5019\u6216\u660e\u5e74\u521d\u5b8c\u6210\u3002 \u8fd9\u4e9b\u6700\u7ec8\u7684\u52a8\u7269\u7814\u7a76\u5bf9\u4e8e\u786e\u5b9a\u7ed9\u836f\u65b9\u6848\u4ee5\u53ca\u5728\u5f00\u59cb\u4eba\u4f53\u8bd5\u9a8c\u4e4b\u524d\u786e\u5b9aARG-007\u7684\u5b89\u5168\u6027\u662f\u81f3\u5173\u91cd\u8981\u7684\u3002 Linear Clinical Research\u4f19\u4f34\u5173\u7cfb \u4e3a\u4e86\u51c6\u5907\u8fd9\u9879\u8bd5\u9a8c\uff0cArgenica\u5728\u4e0a\u4e2a\u6708\u4e0b\u65ec\u4e0e\u73c0\u65af\u7684\u4e34\u5e8a\u7814\u7a76\u673a\u6784\u7ebf\u6027\u4e34\u5e8a\u7814\u7a76\u8fdb\u884c\u4e86\u5408\u4f5c\u3002 Linear\u6709\u4e00\u4e2a\u4e13\u95e8\u5efa\u9020\u7684\u8bbe\u65bd\uff0c\u5728\u5c3c\u5fb7\u5170\u7684QEII\u533b\u7597\u4e2d\u5fc3\u8fd0\u4f5c\uff0c\u5e76\u6709\u4e00\u4e2a\u7ea629,000\u540d\u5065\u5eb7\u5fd7\u613f\u8005\u7684\u6570\u636e\u5e93\uff0c\u5c06\u7528\u4f5c\u8bd5\u9a8c\u7684\u62db\u52df\u5e93\u3002 Argenica\u5df2\u8058\u8bf7Linear\u516c\u53f8\u627f\u62c5\u8bd5\u9a8c\u7684\u521d\u6b65\u5de5\u4f5c\uff0c\u5305\u62ec\u719f\u6089\u65b9\u6848\u3001\u5efa\u7acb\u4e34\u5e8a\u573a\u6240\u7ba1\u7406\u3001\u51c6\u5907\u4f26\u7406\u63d0\u4ea4\u3001\u9884\u8ba2\u8bd5\u9a8c\u671f\u95f4\u7684\u4e34\u5e8a\u5e8a\u4f4d\u4ee5\u53ca\u5efa\u7acb\u4e34\u5e8a\u7814\u7a76\u76d1\u6d4b\u3002 \u7b2c\u4e00\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c \u8be5\u8bd5\u9a8c\u5c06\u5305\u62ec\u56db\u4e2a\u961f\u5217\uff0c\u6bcf\u4e2a\u961f\u5217\u5305\u62ec8\u540d\u5065\u5eb7\u7684\u4eba\u3002 \u6bcf\u4e2a\u961f\u5217\u5c06\u63a5\u53d7\u4e0d\u540c\u5242\u91cf\u7684ARG-007\u3002\u5728\u6bcf\u4e2a\u961f\u5217\u4e2d\uff0c6\u540d\u53d7\u8bd5\u8005\u5c06\u63a5\u53d7\u6307\u5b9a\u5242\u91cf\u7684ARG-007\uff0c\u800c2\u540d\u53d7\u8bd5\u8005\u5c06\u63a5\u53d7\u5b89\u6170\u5242\u3002 Argenica\u9884\u8ba1\uff0c1\u671f\u4e34\u5e8a\u8bd5\u9a8c\u5c06\u9700\u89816\u4e2a\u6708\u7684\u65f6\u95f4\u5b8c\u6210\uff0c\u5e76\u5728\u5065\u5eb7\u4eba\u7c7b\u60a3\u8005\u4e2d\u4f7f\u7528ARG-007\u65f6\u63d0\u4f9b\u6709\u5173\u5176\u5b89\u5168\u6027\u3001\u8010\u53d7\u6027\u548c\u836f\u4ee3\u52a8\u529b\u5b66\u7684\u6570\u636e\u3002 \u8be5\u8bd5\u9a8c\u8fd8\u5c06\u8bc4\u4f30\u7ed9\u836f\u5242\u91cf\u7684\u5b89\u5168\u6027\uff0c\u5e76\u76d1\u6d4b\u4efb\u4f55\u4e0d\u826f\u53cd\u5e94\u548c\u4e00\u822c\u8010\u53d7\u6027\u3002 \u8fdb\u51652\u671f\u4e34\u5e8a\u7814\u7a76 \u6765\u81ea1\u671f\u4eba\u4f53\u7814\u7a76\u7684\u6570\u636e\u5c06\u652f\u63012\u671f\u8bd5\u9a8c\u7684\u8def\u7ebf\u56fe\uff0c\u5176\u4e2dARG-007\u5c06\u7528\u4e8e\u4e2d\u98ce\u60a3\u8005\u3002 ARG-007\u7684\u6700\u7ec8\u76ee\u6807\u662f\u7acb\u5373\u7ed9\u836f\uff0c\u4ee5\u51cf\u5c11\u534a\u6697\u5e26\u7ec6\u80de\u7684\u6b7b\u4ea1\u3002 \u8fd9\u5c06\u6539\u5584\u75c5\u4eba\u7684\u9884\u540e\u5e76\u51cf\u5c11\u6062\u590d\u65f6\u95f4\u3002 Argenica\u6307\u51fa\uff0c1\u671f\u4e34\u5e8a\u6570\u636e\u4e5f\u53ef\u80fd\u7528\u4e8e\u52a0\u901fARG-007\u6cbb\u7597\u5176\u4ed6\u7c7b\u578b\u8111\u635f\u4f24\u7684\u4e34\u5e8a\u5f00\u53d1\uff0c\u5305\u62ec\u56f4\u4ea7\u671f\u7f3a\u6c27\u7f3a\u8840\u6027\u8111\u75c5\u3001\u521b\u4f24\u6027\u8111\u635f\u4f24\u548c\u8111\u9707\u8361\uff0c\u4ee5\u53ca\u624b\u672f\u8bf1\u53d1\u7684\u4e2d\u98ce\u3002 Argenica\u7684\u613f\u666f \u6839\u636eArgenica\u7684\u8bf4\u6cd5\uff0c\u76ee\u524d\u4e2d\u98ce\u60a3\u8005\u7684\u62a4\u7406\u6807\u51c6\u662f\u9488\u5bf9\u4e2d\u98ce\u7684\u6cbb\u7597\u548c\u8bca\u65ad\uff0c\u800c\u4e0d\u662f\u5bf9\u8111\u7ec6\u80de\u7684\u4fdd\u62a4\u3002 \u636e\u4f30\u8ba1\uff0c\u9002\u5f53\u7684\u4e2d\u98ce\u6cbb\u7597\u6bcf\u5ef6\u8fdf\u4e00\u4e2a\u5c0f\u65f6\uff0c\u5927\u8111\u5c31\u4f1a\u8870\u80013.6\u5e74\uff0c\u8fd9\u610f\u5473\u7740\u53ca\u65f6\u8bca\u65ad\u548c\u6cbb\u7597\u5bf9\u75c5\u4eba\u7684\u9884\u540e\u81f3\u5173\u91cd\u8981\u3002 \u5206\u6790\u4eba\u58eb\u9884\u6d4b\uff0c\u52302030\u5e74\uff0c\u5168\u7403\u4e2d\u98ce\u6cbb\u7597\u8d39\u7528\u5c06\u8fbe\u52301830\u4ebf\u6fb3\u5143\u3002 ARG-007\u662f\u4e00\u79cd\u5bcc\u542b\u7cbe\u6c28\u9178\u7684\u9633\u79bb\u5b50\u591a\u80bd\uff0c\u88ab\u8bbe\u8ba1\u7528\u6765\u4fdd\u62a4\u5927\u8111\u7ec4\u7ec7\u5728\u4e2d\u98ce\u671f\u95f4\u514d\u53d7\u635f\u4f24\uff0c\u5e76\u589e\u52a0\u4e2d\u98ce\u540e\u6062\u590d\u7684\u673a\u4f1a\u3002 Argenica\u7684\u613f\u666f\u662f\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u6cbb\u7597\u836f\u7269\uff0c\u5982ARG-007\uff0c\u53ef\u4ee5\u5e2e\u52a9\u4e2d\u98ce\u60a3\u8005\u5728\u5c3d\u53ef\u80fd\u65e9\u7684\u9636\u6bb5\u6700\u5c0f\u5316\u4f24\u5bb3\u548c\u6539\u5584\u7ed3\u679c\u3002<\/p>\n","protected":false},"author":3,"featured_media":13517,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[888],"yoast_head":"\n
Argenica Therapeutics\u5c06\u4e8e\u660e\u5e74\u5e74\u521d\u5f00\u59cb\u7b2c\u4e00\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c<\/title>\n<meta name=\"description\" content=\"\u7ecf\u8fc7\u5e7f\u6cdb\u7684\u7814\u7a76\u548c\u4e34\u5e8a\u524d\u7814\u7a76\uff0cArgenica Therapeutics (ASX: AGN)\u6b63\u51c6\u5907\u4e8e\u660e\u5e74\u7b2c\u4e00\u5b63\u5ea6\u5f00\u59cb\u5176\u5352\u4e2d\u6cbb\u7597\u836f\u7269ARG-007\u76841\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Argenica Therapeutics\u5c06\u4e8e\u660e\u5e74\u5e74\u521d\u5f00\u59cb\u7b2c\u4e00\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c\" \/>\n<meta property=\"og:description\" content=\"\u7ecf\u8fc7\u5e7f\u6cdb\u7684\u7814\u7a76\u548c\u4e34\u5e8a\u524d\u7814\u7a76\uff0cArgenica Therapeutics (ASX: AGN)\u6b63\u51c6\u5907\u4e8e\u660e\u5e74\u7b2c\u4e00\u5b63\u5ea6\u5f00\u59cb\u5176\u5352\u4e2d\u6cbb\u7597\u836f\u7269ARG-007\u76841\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/argenica-therapeutics-start-phase-1-clinical-trials-early-next-year\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2021-10-18T03:35:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T17:51:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Argenica-Therapeutics-ASX-AGN-Phase-1-clinical-trial-stroke-roadmap.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Lorna Nicholas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lorna Nicholas\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/argenica-therapeutics-start-phase-1-clinical-trials-early-next-year\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/argenica-therapeutics-start-phase-1-clinical-trials-early-next-year\/\",\"name\":\"Argenica Therapeutics\u5c06\u4e8e\u660e\u5e74\u5e74\u521d\u5f00\u59cb\u7b2c\u4e00\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2021-10-18T03:35:30+00:00\",\"dateModified\":\"2023-08-29T17:51:32+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60\"},\"description\":\"\u7ecf\u8fc7\u5e7f\u6cdb\u7684\u7814\u7a76\u548c\u4e34\u5e8a\u524d\u7814\u7a76\uff0cArgenica Therapeutics (ASX: AGN)\u6b63\u51c6\u5907\u4e8e\u660e\u5e74\u7b2c\u4e00\u5b63\u5ea6\u5f00\u59cb\u5176\u5352\u4e2d\u6cbb\u7597\u836f\u7269ARG-007\u76841\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/argenica-therapeutics-start-phase-1-clinical-trials-early-next-year\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/argenica-therapeutics-start-phase-1-clinical-trials-early-next-year\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/argenica-therapeutics-start-phase-1-clinical-trials-early-next-year\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Argenica Therapeutics\u5c06\u4e8e\u660e\u5e74\u5e74\u521d\u5f00\u59cb\u7b2c\u4e00\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60\",\"name\":\"Lorna Nicholas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g\",\"caption\":\"Lorna Nicholas\"},\"description\":\"Lorna has more than 15 years' experience as a business\/finance journalist and editor. She has written for numerous industry publications reporting on various sectors, including: resources, energy, construction, biotech, pharma, science and technology, agriculture, and chemicals. Specialising in resources, Lorna has also covered a myriad of small and large cap ASX and dual-listed stocks.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=3\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Argenica Therapeutics\u5c06\u4e8e\u660e\u5e74\u5e74\u521d\u5f00\u59cb\u7b2c\u4e00\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c","description":"\u7ecf\u8fc7\u5e7f\u6cdb\u7684\u7814\u7a76\u548c\u4e34\u5e8a\u524d\u7814\u7a76\uff0cArgenica Therapeutics (ASX: AGN)\u6b63\u51c6\u5907\u4e8e\u660e\u5e74\u7b2c\u4e00\u5b63\u5ea6\u5f00\u59cb\u5176\u5352\u4e2d\u6cbb\u7597\u836f\u7269ARG-007\u76841\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Argenica Therapeutics\u5c06\u4e8e\u660e\u5e74\u5e74\u521d\u5f00\u59cb\u7b2c\u4e00\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c","og_description":"\u7ecf\u8fc7\u5e7f\u6cdb\u7684\u7814\u7a76\u548c\u4e34\u5e8a\u524d\u7814\u7a76\uff0cArgenica Therapeutics (ASX: AGN)\u6b63\u51c6\u5907\u4e8e\u660e\u5e74\u7b2c\u4e00\u5b63\u5ea6\u5f00\u59cb\u5176\u5352\u4e2d\u6cbb\u7597\u836f\u7269ARG-007\u76841\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/argenica-therapeutics-start-phase-1-clinical-trials-early-next-year\/","og_site_name":"smallcapsCN","article_published_time":"2021-10-18T03:35:30+00:00","article_modified_time":"2023-08-29T17:51:32+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Argenica-Therapeutics-ASX-AGN-Phase-1-clinical-trial-stroke-roadmap.jpg","type":"image\/jpeg"}],"author":"Lorna Nicholas","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Lorna Nicholas"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/argenica-therapeutics-start-phase-1-clinical-trials-early-next-year\/","url":"https:\/\/smallcapscn.x5view.co\/argenica-therapeutics-start-phase-1-clinical-trials-early-next-year\/","name":"Argenica Therapeutics\u5c06\u4e8e\u660e\u5e74\u5e74\u521d\u5f00\u59cb\u7b2c\u4e00\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2021-10-18T03:35:30+00:00","dateModified":"2023-08-29T17:51:32+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60"},"description":"\u7ecf\u8fc7\u5e7f\u6cdb\u7684\u7814\u7a76\u548c\u4e34\u5e8a\u524d\u7814\u7a76\uff0cArgenica Therapeutics (ASX: AGN)\u6b63\u51c6\u5907\u4e8e\u660e\u5e74\u7b2c\u4e00\u5b63\u5ea6\u5f00\u59cb\u5176\u5352\u4e2d\u6cbb\u7597\u836f\u7269ARG-007\u76841\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/argenica-therapeutics-start-phase-1-clinical-trials-early-next-year\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/argenica-therapeutics-start-phase-1-clinical-trials-early-next-year\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/argenica-therapeutics-start-phase-1-clinical-trials-early-next-year\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Argenica Therapeutics\u5c06\u4e8e\u660e\u5e74\u5e74\u521d\u5f00\u59cb\u7b2c\u4e00\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60","name":"Lorna Nicholas","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g","caption":"Lorna Nicholas"},"description":"Lorna has more than 15 years' experience as a business\/finance journalist and editor. She has written for numerous industry publications reporting on various sectors, including: resources, energy, construction, biotech, pharma, science and technology, agriculture, and chemicals. Specialising in resources, Lorna has also covered a myriad of small and large cap ASX and dual-listed stocks.","url":"https:\/\/smallcapscn.x5view.co\/?author=3"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/4012"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4012"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/4012\/revisions"}],"predecessor-version":[{"id":13516,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/4012\/revisions\/13516"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/13517"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4012"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4012"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4012"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}